刚刚！IPO审1过1

Core Viewpoint - Changzhou Baierji Biotechnology Co., Ltd. has received approval for its IPO application from the Beijing Stock Exchange, indicating a positive outlook for the company's growth and market entry [1]. Group 1: Company Overview - The company specializes in the research, production, and sales of biomedical materials, with a focus on innovative tissue repair and regeneration materials, and also engages in the production of functional skincare products containing hyaluronic acid derivatives [3]. - Established in April 2008, the company transitioned to a joint-stock company in May 2023, with a total share capital of 60 million shares prior to the IPO [3]. - As of the latest disclosure, the company operates seven subsidiaries across various cities in China and employs a total of 234 staff members [3]. Group 2: Shareholding Structure - The controlling shareholder and actual controller of the company is Shu Xiaozheng, who directly holds 27.84% of the shares and controls an additional 4.51% through related entities, totaling 32.36% of voting rights [4]. - Shu Xiaozheng has been the chairman and general manager since the company's inception, significantly influencing its operational decisions [4]. Group 3: Financial Performance - The company's revenue for the reporting period was 150.74 million yuan, 198.18 million yuan, 231.23 million yuan, and 141.46 million yuan, with net profits of 27.32 million yuan, 45.12 million yuan, 53.69 million yuan, and 41.29 million yuan respectively [5]. - The total assets as of June 30, 2025, are approximately 337.23 million yuan, with total equity of about 282.36 million yuan [6]. - The company has maintained a gross profit margin of around 81% to 82% over the past few years, indicating strong profitability [6]. Group 4: Listing Standards - The company has chosen to meet the listing standards set forth in the Beijing Stock Exchange's regulations, which require a minimum market value of 200 million yuan, net profits of at least 15 million yuan in the last two years, and an average return on equity of no less than 8% [8]. Group 5: Inquiry on Performance Sustainability - The company has been asked to provide a detailed explanation regarding the sustainability of its performance growth, including the market size and growth trends of its main products, as well as the progress of research and market development for products beyond its current offerings [9].